Patent firm strengthens life sciences team with new promotions
AdamsonJones, a growing East-Midlands based firm of patent attorneys and trade mark attorneys, is pleased to announce that David Gwilliam, Eilidh Pugh and Jenny Vaughan have all been promoted to the position of Partner.
Simon Cooper (managing director) with Eilidh Pugh, David Gwilliam and Jenny Vaughan (l-r)
These new promotions strengthen the firm’s life sciences team, an area of technical expertise that has been at the core of AdamsonJones since it was founded nearly twenty years’ ago by Dr Steve Jones. Indeed, AdamsonJones’ head office has been based at BioCity Nottingham, the UK’s largest bioscience and healthcare innovation centre, since 2004, allowing the firm to best serve the needs of businesses operating in the life sciences sector.
Jenny, David and Eilidh are members of the firm’s expanding team of patent attorneys, offering legal and technical expertise in the life sciences, including pharmaceuticals and chemistry, medical devices, and biotechnology, which has been very much in demand from local, national and international businesses.
Jenny joined AdamsonJones in 2017 and has over 25 years’ experience in the intellectual property (IP) industry. Jenny started her career with industry roles at several large multinational companies, firstly in the speciality chemicals area and then in pharmaceuticals. She spent a number of years working in Sweden and travelling to the US, Australia and around Europe liaising with research establishments and patent attorney firms. On her return to the UK, Jenny continued working in the pharmaceutical and chemical industries, firstly in in-house roles and then as an independent patent attorney on a contract basis to several large companies in the human health, animal health and general chemistry areas. Jenny continues to have a strong interest in human health, animal health and the environment, working with corporate and individual clients alike.
David joined AdamsonJones in 2008 and is a Chartered (UK) Patent Attorney, a European Patent Attorney and a Chartered Trade Mark Attorney. David's patent practice covers healthcare and bioscience with a particular focus on medical devices, wound care, therapeutic antibodies, protein formulations and recombinant DNA technology, and David’s trade mark practice is also focused on healthcare and pharmaceuticals but covers a wide range of business sectors. David has worked on behalf of companies such as Pfizer Inc, Janssen Biotech Inc, Genzyme Corporation (a subsidiary of Sanofi), Vectura Ltd, Brightwake Ltd and Haemostatix Ltd, as well as universities including Cornell University, the University of Rochester and New York University, and also has considerable experience of working with small start-ups and university spin-outs. David holds an MSc in Cancer Immunotherapy and a BSc (Hons) in Biochemistry & Genetics from the University of Nottingham and worked in industry at MedImmune before joining AdamsonJones.
Eilidh joined AdamsonJones in 2004 and qualified as both a Chartered (UK) Patent Attorney and a European Patent Attorney in 2008. Her practice is centred on prosecution, advice work and patent drafting across the chemical, pharmaceutical and biomedical fields. In particular, Eilidh has experience with small molecule therapeutics, pharmaceutical formulations, absorbent articles and materials, polymeric films and fibres, personal care products including skin, hair and sun care products, botanical extracts, dyes and colourants, absorption enhancers, bioseparation technologies and carbon dioxide absorbents. Eilidh has a wide range of clients, many of them SMEs, but also universities and she has considerable experience looking after large international patent portfolios for multinational clients.
With such a genuine passion for the life sciences, it’s perhaps no surprise that AdamsonJones has been listed in the Legal 500 UK rankings since 2015 and is noted for having “particular expertise in the fields of life sciences” and having “substantial expertise of acting for SMEs in the fields of pharmaceuticals and medical devices”.